BRIEF RESEARCH REPORT article
Front. Immunol.
Sec. Alloimmunity and Transplantation
Daratumumab Combined with Anti-CD20 Therapy in Pediatric and Adult Refractory Idiopathic Nephrotic Syndrome: Single-Center Experience
Provisionally accepted
Hamza Naciri Bennani*
Thomas Sandaye
Quentin CharroyerAurelie EtangsaleHenri Vacher Coponat
Marie JulienVincent MearOlivier DunandLudovic Di Ascia- Centre Hospitalier Universitaire de La Réunion, Saint-Denis, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background : Refractory idiopathic nephrotic syndrome (INS), in native kidneys or post-transplant, represents a major therapeutic challenge due to its high risk of progressing to end-stage renal disease. Patients often resist anti-CD20 therapy and require prolonged apheresis. Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has demonstrated promising efficacy in case reports when combined with anti-CD20, but evidence remains limited. Methods : We conducted a single-center retrospective study including four patients (two pediatric, two adult, including one renal transplant) with INS refractory to conventional therapies (corticosteroids, calcineurin inhibitors, mycophenolate mofetil, anti-CD20 antibodies, and/or apheresis). All Patients received daratumumab combined with anti-CD20 therapy at University Hospital of La Réunion between 2022 and 2025. Clinical and laboratory data were extracted from medical records. Renal response was defined as complete remission (CR) or partial remission (PR). Results : The mean patient age was 20 ± 13 years (range: 8–40), with a male-to-female ratio of 3:1. Median follow-up after daratumumab administration was 5 months (range: 2–12). All patients achieved CR with a median time to response of 25 days (range: 14–30). Previously apheresis-dependent patients were able to discontinue sessions. Two patients developed infections (herpetic and SARS-CoV-2 pneumonia complicated by pneumococcal bacteremia), all resolving favorably. Renal function remained stable. Conclusion : Combined daratumumab and anti-CD20 therapy appears to be an effective rescue strategy for refractory INS, in native kidneys and post-transplant. It induces rapid and sustained remission, enabling discontinuation of apheresis. Prospective studies are warranted to optimize treatment regimens and identify predictive biomarkers of response.
Keywords: Idiopathic nephrotic syndrome, Daratumumab, Plasma Cells, Anti-CD20, Refractory nephrotic syndrome, Kidney Transplantation
Received: 10 Oct 2025; Accepted: 19 Nov 2025.
Copyright: © 2025 Naciri Bennani, Sandaye, Charroyer, Etangsale, Vacher Coponat, Julien, Mear, Dunand and Di Ascia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hamza Naciri Bennani, hamza.naciri-bennani@chu-reunion.fr
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.